Heidi West discusses how academia, government and the pharmaceutical industry can work together to potentially repurpose drugs for the treatment of COVID-19.
List view / Grid view
Filter the results
Pfizer and BioNTech have initiated Phase I/II trials in the US to determine the safety and optimal dose of four mRNA COVID-19 vaccine candidates.
A Phase I/II clinical trial for BioNTech's BNT162 vaccine programme to prevent COVID-19 infection has been granted approval in Germany.
The FDA has handed a warning letter to an Indian manufacturing facility for inadequate sterility testing and environmental monitoring.
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
Lilly, Merck and Pfizer have announced how they will enable their employees to volunteer in programmes to combat COVID-19 while on base pay.
As the world rushes to identify the best coronavirus treatments and vaccines, John Cahill rounds up the latest developments in potential COVID-19 therapies.
Once patents expire for biologic medicines, a market opportunity opens up for biosimilars, a cheaper alternative. With more patents due to expire soon, what will the future look like for biologic medicines?
A report released by pharmaceutical industry leaders in the US demonstrates how blockchain helps to track and trace prescription medicines.
New research has suggested that the expiration of biologics patents will be the factor that positively impacts US pharma the most this year.
A new report has revealed Johnson & Johnson as the most valuable pharmaceutical brand, despite a decrease in profits from last year.
The pharmaceutical industry saw some notable mergers and acquisitions in 2019; this article lists the top 10 by transaction size.
The NICE committee has made palbociclib with fulvestrant available on the Cancer Drug Fund for patients with hormone receptor-positive, HER2-negative, advanced breast cancer.